Technical Analysis for CSTL - Castle Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 28.40 | -0.18% | -0.05 |
CSTL closed down 1.45 percent on Wednesday, November 20, 2024, on 75 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | -0.18% | |
| Lower Bollinger Band Walk | Weakness | -0.18% | |
| Inside Day | Range Contraction | -0.18% | |
| Lower Bollinger Band Touch | Weakness | -0.18% | |
| Oversold Stochastic | Weakness | -0.18% | |
| Bullish Engulfing | Bullish | -1.63% | |
| Lower Bollinger Band Walk | Weakness | -1.63% | |
| Outside Day | Range Expansion | -1.63% | |
| Lower Bollinger Band Touch | Weakness | -1.63% | |
| Oversold Stochastic | Weakness | -1.63% |
| Alert | Time |
|---|---|
| Possible NR7 | about 20 hours ago |
| Possible Inside Day | about 20 hours ago |
| Fell Below Lower Bollinger Band | about 21 hours ago |
| 60 Minute Opening Range Breakdown | about 22 hours ago |
| Lower Bollinger Band Support | about 23 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/31/2024
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Melanoma Medical Test Gene Expression Metastasis Dsw Uveal Melanoma
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Melanoma Medical Test Gene Expression Metastasis Dsw Uveal Melanoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.84 |
| 52 Week Low | 16.965 |
| Average Volume | 412,447 |
| 200-Day Moving Average | 24.95 |
| 50-Day Moving Average | 31.05 |
| 20-Day Moving Average | 31.91 |
| 10-Day Moving Average | 30.91 |
| Average True Range | 1.78 |
| RSI (14) | 38.27 |
| ADX | 30.73 |
| +DI | 13.25 |
| -DI | 21.77 |
| Chandelier Exit (Long, 3 ATRs) | 30.49 |
| Chandelier Exit (Short, 3 ATRs) | 32.59 |
| Upper Bollinger Bands | 36.05 |
| Lower Bollinger Band | 27.78 |
| Percent B (%b) | 0.08 |
| BandWidth | 25.89 |
| MACD Line | -0.66 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.6736 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 30.13 | ||||
| Resistance 3 (R3) | 30.06 | 29.43 | 29.85 | ||
| Resistance 2 (R2) | 29.43 | 29.00 | 29.47 | 29.76 | |
| Resistance 1 (R1) | 28.94 | 28.74 | 28.63 | 29.01 | 29.66 |
| Pivot Point | 28.31 | 28.31 | 28.15 | 28.35 | 28.31 |
| Support 1 (S1) | 27.82 | 27.88 | 27.51 | 27.89 | 27.24 |
| Support 2 (S2) | 27.19 | 27.62 | 27.23 | 27.14 | |
| Support 3 (S3) | 26.70 | 27.19 | 27.05 | ||
| Support 4 (S4) | 26.77 |
